HSBC Holdings
FDMT icon

HSBC Holdings’s 4D Molecular Therapeutics FDMT Stock Holding History

HSBC Holdings’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-48,806
Closed -$404K – 3007
2025
Q3 		$404K Sell
48,806
-2,364
-5% -$14.1K ﹤0.01% 2207
2025
Q2 		$192K Sell
51,170
-1,001
-2% -$3.52K ﹤0.01% 2695
2025
Q1 		$166K Buy
52,171
+17,758
+52% +$83.7K ﹤0.01% 2669
2024
Q4 		$190K Buy
34,413
+16,142
+88% +$127K ﹤0.01% 2734
2024
Q3 		$196K Buy
18,271
+6,361
+53% +$106K ﹤0.01% 2621
2024
Q2 		$246K Buy
+11,910
New +$299K ﹤0.01% 2430
2024
Q1 		– Sell
-18,654
Closed -$384K – 3109
2023
Q4 		$384K Buy
+18,654
New +$245K ﹤0.01% 2171

Other funds holding FDMT

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

HSBC Holdings's FDMT Position: Q4 2025 in Review

HSBC Holdings sold out of 4D Molecular Therapeutics (FDMT) in Q4 2025, closing a stake of 48,806 shares — an estimated $404K sold.

HSBC Holdings first reported a position in FDMT in Q4 2023 and held it in 7 quarters. The position peaked at $404K in Q3 2025. 153 funds tracked by Wall St. Rank hold FDMT as of Q4 2025.

  • HSBC Holdings reported no remaining 4D Molecular Therapeutics position as of Q4 2025 after selling out during the quarter.
  • HSBC Holdings sold 48,806 4D Molecular Therapeutics shares in Q4 2025, an estimated $404K.
  • HSBC Holdings first reported a position in 4D Molecular Therapeutics in Q4 2023 and held it in 7 quarters.
  • HSBC Holdings's 4D Molecular Therapeutics position peaked at $404K in Q3 2025.
  • 153 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q4 2025.

Based on HSBC Holdings's 13F filing for Q4 2025, filed 6 Mar 2026.